In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the effect of tirzepatide treatment on body weight in women was examined according to the stage of menopause.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Supply models in Switzerland
Health 2040 research project
- Pathogenesis, diagnostics and therapeutic interventions
Sarcopenia in Parkinson’s disease
- Casuistry
63-year-old with tracheobronchopathia osteoplastica
- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline
Management of acute coronary syndrome
- Pustular psoriasis
What is known about inflammatory mechanisms in PPP and GPP?
- Diabetes-related cardiovascular diseases
Ferroptosis: key mechanisms and novel therapeutic approaches
- Atrial fibrillation
What’s new with the “pace-and-ablate” strategy?
- De-escalation strategies